Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 27% ± 11% | |
peripheral blood | 15 studies | 29% ± 11% | |
intestine | 7 studies | 26% ± 6% | |
liver | 5 studies | 20% ± 4% | |
brain | 5 studies | 27% ± 4% | |
uterus | 4 studies | 44% ± 6% | |
breast | 4 studies | 26% ± 3% | |
kidney | 3 studies | 25% ± 2% | |
bone marrow | 3 studies | 24% ± 4% | |
adipose | 3 studies | 26% ± 8% | |
lymph node | 3 studies | 32% ± 6% | |
skin | 3 studies | 30% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4827.23 | 1443 / 1445 | 98% | 42.38 | 180 / 183 |
lung | 100% | 9411.80 | 576 / 578 | 96% | 28.73 | 1112 / 1155 |
intestine | 100% | 4660.23 | 964 / 966 | 96% | 25.33 | 506 / 527 |
stomach | 99% | 4827.12 | 356 / 359 | 95% | 24.63 | 271 / 286 |
bladder | 100% | 2412.10 | 21 / 21 | 90% | 21.51 | 454 / 504 |
pancreas | 96% | 3103.38 | 314 / 328 | 94% | 24.24 | 167 / 178 |
uterus | 97% | 4851.35 | 165 / 170 | 87% | 25.90 | 400 / 459 |
thymus | 100% | 5225.88 | 650 / 653 | 83% | 25.04 | 502 / 605 |
breast | 100% | 7075.16 | 458 / 459 | 78% | 26.64 | 874 / 1118 |
prostate | 98% | 3342.21 | 241 / 245 | 76% | 15.98 | 382 / 502 |
kidney | 96% | 4612.13 | 85 / 89 | 71% | 20.75 | 641 / 901 |
liver | 100% | 5248.78 | 226 / 226 | 66% | 9.18 | 266 / 406 |
ovary | 98% | 3592.14 | 176 / 180 | 67% | 8.91 | 289 / 430 |
skin | 99% | 6029.63 | 1786 / 1809 | 65% | 9.98 | 305 / 472 |
spleen | 100% | 5118.12 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 6821.91 | 1197 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 95% | 3842.98 | 1274 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 4087.16 | 874 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 37.06 | 40 / 45 |
adrenal gland | 62% | 1078.49 | 159 / 258 | 23% | 3.54 | 54 / 230 |
heart | 83% | 2413.33 | 717 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 79% | 23.63 | 23 / 29 |
brain | 9% | 120.65 | 234 / 2642 | 27% | 3.68 | 191 / 705 |
muscle | 12% | 167.54 | 99 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.07 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032980 | Biological process | keratinocyte activation |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0002224 | Biological process | toll-like receptor signaling pathway |
GO_0090594 | Biological process | inflammatory response to wounding |
GO_0010468 | Biological process | regulation of gene expression |
GO_0002544 | Biological process | chronic inflammatory response |
GO_0030216 | Biological process | keratinocyte differentiation |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0070897 | Biological process | transcription preinitiation complex assembly |
GO_0045063 | Biological process | T-helper 1 cell differentiation |
GO_0140459 | Biological process | response to Gram-positive bacterium |
GO_0072539 | Biological process | T-helper 17 cell differentiation |
GO_0097398 | Biological process | cellular response to interleukin-17 |
GO_0061436 | Biological process | establishment of skin barrier |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_2000321 | Biological process | positive regulation of T-helper 17 cell differentiation |
GO_0072718 | Biological process | response to cisplatin |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0006338 | Biological process | chromatin remodeling |
GO_0048873 | Biological process | homeostasis of number of cells within a tissue |
GO_0048536 | Biological process | spleen development |
GO_1990117 | Biological process | B cell receptor apoptotic signaling pathway |
GO_0051593 | Biological process | response to folic acid |
GO_1904019 | Biological process | epithelial cell apoptotic process |
GO_0042789 | Biological process | mRNA transcription by RNA polymerase II |
GO_0002317 | Biological process | plasma cell differentiation |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0097194 | Biological process | execution phase of apoptosis |
GO_0042100 | Biological process | B cell proliferation |
GO_0045190 | Biological process | isotype switching |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0002456 | Biological process | T cell mediated immunity |
GO_0043616 | Biological process | keratinocyte proliferation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0016607 | Cellular component | nuclear speck |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0005515 | Molecular function | protein binding |
GO_0070974 | Molecular function | POU domain binding |
Gene name | NFKBIZ |
Protein name | NFKB inhibitor zeta NF-kappa-B inhibitor zeta (I-kappa-B-zeta) (IkB-zeta) (IkappaBzeta) (IL-1 inducible nuclear ankyrin-repeat protein) (INAP) (Molecule possessing ankyrin repeats induced by lipopolysaccharide) (MAIL) |
Synonyms | IKBZ INAP |
Description | FUNCTION: Involved in regulation of NF-kappa-B transcription factor complexes . Inhibits NF-kappa-B activity without affecting its nuclear translocation upon stimulation . Inhibits DNA-binding of RELA and NFKB1/p50, and of the NF-kappa-B p65-p50 heterodimer and the NF-kappa-B p50-p50 homodimer . Seems also to activate NF-kappa-B-mediated transcription . In vitro, upon association with NFKB1/p50 has transcriptional activation activity and, together with NFKB1/p50 and RELA, is recruited to LCN2 promoters . Promotes transcription of LCN2 and DEFB4 . Is recruited to IL-6 promoters and activates IL-6 but decreases TNF-alpha production in response to LPS (By similarity). Seems to be involved in the induction of inflammatory genes activated through TLR/IL-1 receptor signaling (By similarity). Involved in the induction of T helper 17 cells (Th17) differentiation upon recognition of antigen by T cell antigen receptor (TCR) (By similarity). . |
Accessions | ENST00000461724.5 C9JZ23 C9J5G8 ENST00000326172.9 [Q9BYH8-1] Q9BYH8 ENST00000483180.5 ENST00000477601.1 ENST00000491281.1 H7C5S1 ENST00000326151.9 [Q9BYH8-3] ENST00000394054.6 [Q9BYH8-2] C9J5I7 |